The use of animal retroviruses as proviral tags has been highly successful in revealing genes and pathways involved in murine leukemia and mammary carcinoma (Cecconi and Meyer, 2000; Evans et al., 1997; Jonkers and Berns, 1996) . Retroviral insertional mutagenesis induces a high incidence of neoplasia in animals and studies based on ampli®cation and sequencing of proviral integrations have led recently to isolate a large number of candidate leukemia genes (Largaespada, 2000; Li et al., 1999) . Human oncogenic viruses acting by insertional mutagenesis like animal retroviruses have never been described. However, Hepadnaviruses, which are small, circular, hepatotropic DNA viruses, have been classi®ed as Pararetroviruses since they share partial genomic sequence, replication strategy and genome organization similarities with slow oncogenic retroviruses (Robinson et al., 1987) . Hepadnaviruses have strict host-speci®city and similar genomic organization (Fourel and Tiollais, 1994) . They include HBV, infecting humans, GSHV (Ground Squirrel Hepatitis Virus), WHV (Woodchuck Hepatitis Virus), DHV (Duck Hepatitis Virus) and HHBV (Heron Hepatitis Virus). Interestingly, WHV induces liver cancer in 100% of animals infected at birth. Molecular studies have shown that, in 80% of cases or more, it acts by insertional mutagenesis, like a slow oncogenic retrovirus, and cis-activates oncogenes of the Myc family (Buendia, 1992) .
In humans, epidemiological studies have demonstrated the association of HBV chronic infection and development of hepatocellular carcinoma (HCC) (Johnson, 1994) . HCC develops after a long delay, generally of 15 to 30 years, from HBV infection. Long lasting viral multiplication and HBV protein expression are known to stimulate the host immune response and thus liver in¯ammation and ®brosis (Chisari, 1995) . This process modi®es cell-to-cell and cell-to-extracellular matrix interactions and induces the synthesis of cytokines which may trigger liver cell proliferation. Therefore, chronic liver disease with persistence of the HBV genome is a major risk factor for HCC. Besides this mechanism, a direct role of HBV in liver carcinogenesis has been suggested since HBV-related HCC may also develop without a background of chronic liver in¯ammation . The HBV X protein has a transactivating eect on both cellular and viral genes and its expression has been shown to interfere with the control of cell growth and apoptosis. In vitro studies and in vivo experiments in transgenic mice have suggested its possible role in liver carcinogenesis. However, no studies have demonstrated up to now the transforming or tumorigenic eect of X gene sequences directly isolated from human tumorous liver tissues . HBV DNA integration into cellular DNA is an early event during chronic HBV infection and the majority of HCC tissues exhibits clonal expansion of tumor cells carrying the same integration site. HBV genome integration and reintegration events allow the persistence of viral sequences and may lead to chromosomal rearrangements, deletion of both viral and cellular DNA and synthesis of truncated, transactivating, PreS 2 /S and viral proteins . In addition, HBV DNA integration may act by insertional mutagenesis. In fact, the HBV genome has been found integrated into the Retinoic Acid Receptor Beta (Dejean et al., 1986) and the Cyclin A2 (Wang et al., 1990) gene in two isolated HCCs. Interestingly, further analyses have demonstrated that the mutation of these two genes identi®ed in the tumorous tissue has transforming and tumorigenic properties (Berasain et al., 1998; Garcia et al., 1993) . Thus, studies on HBV-related insertional mutagenesis allowed to isolate two previously unknown human genes, which play a major role in cell dierentiation and proliferation, and to prove their role in carcinogenesis.
Over the past 20 years, conventional cloning strategies have been applied to HCCs to identify cellular genes at the HBV integration site. A limited number of tumors has been explored by these long and cumbersome methods and only very few genes have been identi®ed . Chromosomal studies have also shown that, at variance with slow oncogenic retroviruses, HBV does not seem to have common integration sites in the cellular DNA (Matsubara and Tokino, 1990) . The general conclusion of these analyses was that HBV-related insertional mutagenesis is probably an anectodical event in HCC.
Despite this discouraging background, we decided to further explore the frequence of HBV related insertional mutagenesis and test the hypothesis that the natural tagging of cellular genes by HBV could be used to identify cancer-related genes.
We have developed a PCR-based assay which enables the rapid screening of HBV/cellular DNA junctions using HBV-X and Alu-speci®c primers (Alu-PCR) (Minami et al., 1995) (Figure 1 ). The HBV X gene is frequently interrupted by the viral DNA integration (Schluter et al., 1994) . Circular HBV DNAs coexist in liver tissues with integrated viral genomes and the cellular sequence targeted by the virus is completely unknown. In order to overcome these limitations and avoid undesirable ampli®cations between Alu sequences, primers are synthetized with dUTP instead of dTTP and destroyed after 10 initial cycles of PCR. Only speci®cally targeted sequences are then ampli®ed with primers to the HBV X region and to a tag sequence introduced in the Alu-speci®c primer. By using this approach, we have now isolated 21 HBV integration sites from 18 HCCs. Eight junctions exhibit repetitive sequences, ®ve of them of LINE1 type. Seven HBV/cellular DNA junctions contain unique cellular sequences which, at present, do not correspond to any coding sequence in data banks.
The HBV genome was found to be integrated into dierent cellular genes in six independent tumors (Table 1 and Figure 2 ). Remarkably, ®ve of them belong to gene families involved in cell proliferation and/or viability. The ®fth one is expressed in fetal and cancer tissues. Southern blot analyses performed in three tumors (77T, 83T, 86T) and repeated analyses on dierent DNA samples from the same tumor showed that the HBV-DNA integration in the target gene took place in about all the tumor cells (data not shown).
In tumor 54T, HBV DNA integration occurred into an intronic sequence (position 222267 to 222742 in the supercontig NT011005) of the Nuclear Matrix Protein p84 (NMP p84, code gene: XM 008756). The HBV and the NMP p84 ORFs were found in the same orientation. The Nuclear Matrix Protein p84 gene encodes a nuclear protein which has been shown to bind p110 RB in its N-terminal region (Durfee et al., 1994) . This binding would contribute to, and concentrate the p110 RB protein to subnuclear regions where active forms of several target proteins (transcription factors) would be located. NMP p84 is therefore expected to participate in the control of the cell cycle.
In tumor 86T, HBV DNA integration occurred in frame in the third exon of the Sarco/Endoplasmic Reticulum Calcium ATPase-1 (SERCA1) gene (SER-CA1 genomic sequence accession number U96773, nt 1979 ± 2293). SERCA proteins play a pivotal role in regulating cellular calcium which, in turn, acts as an intracellular messenger involved in a broad range of cellular activities, including cell proliferation and death (Berridge et al., 1998) . In the tumor, HBV integration cis-activated HBV-X/SERCA1 fusion transcripts and their in vitro expression has been shown to induce ER calcium depletion and apoptosis (Chami et al., 2000) . Although the pleiotropic role of cellular calcium, including on cell growth and apoptosis, has been repeatedly shown in the past, this is the ®rst report implicating the clonal mutation of a SERCA gene in a tumor cell proliferation. This study also led to discover new truncated SERCA1 proteins involved in the control of apoptosis (Chami et al., 2001) .
In tumor 100T, HBV DNA integration was found next to a 258 bp cellular sequence containing a 115 bp stretch identical to the Thyroid Hormone Receptor Associated Protein-150 alpha (TRAP-150 alpha) gene (TRAP-150 genomic sequence accession number AL360074, nt 103283 ± 103541 and TRAP150 cDNA sequence accession number AF117756, nt 2119 ± 2233). The HBV and TRAP-150 alpha ORF were found in the same orientation. TRAP proteins are coactivators of nuclear receptors, including thyroid receptor, required for the formation of functional transcriptional preinitiation complexes on target genes (Ito et al., 1999) . Thyroid hormone is a major regulator of liver cell proliferation and mutant thyroid hormone nuclear receptors have been described in HCC cells (Lin et al., 1999) . However, the precise biological eect of the human TRAP-150 alpha gene is still unknown (RG Roeder, personal communication) . It could participate in gene-or activator-selective cofactor complexes. Our preliminary data indicate that TRAP-150 alpha is involved in the control of apoptosis (Y Murakami et al., in preparation) . The present ®nding of its mutation in a human tumorous tissue strongly suggests its implication in liver carcinogenesis.
In tumor 77T, HBV DNA was found next to a 485 bp cellular sequence identical to part of the Minichromosome Maintenance Protein (MCM) 2/3/5 gene-like sequence on chromosome 20p12.3-13 (MCM2/3/5 gene-like genomic sequence accession number AL035461, nt 51574 ± 52059). The HBV and MCM8 ORF were found in the opposite orientation. The six members of the MCM protein family (MCM 2 ± 7) form a complex with DNA helicase activity which controls DNA replication (Tye, 1999). MCM Figure 1 Schematic representation of the technical protocol applied to isolate HBV/cellular DNA junctions (Minami et al., 1995) proteins have been reported to be highly expressed in proliferating and neoplastic tissues (Freeman et al., 1999; Todorov et al., 1998) . Our ®nding allowed us to clone the complete cDNA sequence of this new human MCM gene, that we named human MCM8 (hMCM8) (D Gozuacik et al., submitted). In order to study the expression of the new MCM gene in the tumor and adjacent liver, we have generated a polyclonal antibody raised to a N-terminal peptide sequence speci®c to hMCM8. The Western blot analysis showed that a smaller hMCM8 protein (33 kDa) is selectively expressed in the tumorous (77T) as compared to the non tumorous tissue (Figure 3c ). The size of this protein is consistent with a C-terminally truncated hMCM8 protein derived from a premature stop codon introduced by the HBV sequence (in the`reverse orientation') (predicted size: 32.8 kDa). Work is in progress to clone the cDNA encoding this short hMCM8 protein.
In tumor 83T, HBV DNA integration was found next to a 239 bp cellular sequence identical to a sequence located upstream to the Human Telomerase Reverse Transcriptase (hTERT) gene promoter, (hTERT genomic sequence accession number AF128893, nt 240 ± 478). The HBV and hTERT ORF were found in opposite orientations. The implication of hTERT gene in cancer is already well established in the literature. In fact, telomerase is involved in the process of cell immortalization and is expressed in the majority of human malignancies (Hanahan and Weinberg, 2000; Meyerson, 2000) . This case is relevant since it further supports the hypothesis that HBV integration targets genes involved in the tumorigenic process. The Western blot analysis of the tumor 83T with the anti-hTERT antibody showed a hyperexpressed band (170 kDa) in addition to the hTERT regular hyperexpressed band (136 kDa) in the tumor as compared to the non tumorous tissue (Figure 3d ). It is presently dicult to explain the larger size of the additional TERT protein in the tumor (the HBV integration took place 10.8 kb upstream the hTERT ATG); one may hypothesize that the HBV enhancer could have activated the expression of a normally underexpressed hTERT variant, as previously shown for the SERCA1 gene (Chami et al., 2001) .
Moreover, it has been recently shown that, in the HuH4 human hepatocellular carcinoma-derived cell line (GenBank, AF325900), the HBV genome integration takes place into the promoter region of hTERT, 313 bp before the ATG (Horikawa and Barrett, 2001 ) and cisactivates the hTERT gene expression. Together with our results, this is the ®rst demonstration of a gene targeted by the HBV integration in two independent HCCs.
In tumor FR7, HBV DNA was found next to a 660 bp cellular sequence identical to a genomic clone on chromosome 12p (accession number AC009318, nt 112312 ± 112971). A 190 bp stretch of this sequence is identical to human fetal (accession numbers N67205, H16791) and cancer (neuroblastoma and breast cancer)
86T
Figure 2 HBV DNA integration in six cellular genes. 54T, 86T, 100T, 77T, 83T and FR7 are HCC codes (Table 1) . Open box: HBV X sequence. Number below indicates HBV nucleotide at the HBV/cellular DNA junction (HBV subtype and accession number V00866 was taken as reference sequence.). The double headed arrow marks the size of the cellular sequence obtained by Alu-PCR. Dotted box: cellular region of identity with GenBank sequences. Shaded box: coding sequences. Bold arrowhead: orientation of the ORF derived ESTs (Cancer Genome Anatomy Project, accession numbers AI361463, AA996057). The Genscan analysis showed that the FR7 gene is aǹ unnamed gene' (supercontig NT_009622, position 2129217, AK001927, EST BG741742 and BF572281) without any homology with known genes or domains. This analysis also predicted a FR7 mRNA of 3847 bp. According to this study, the HBV integration took place in the 3' part of the gene corresponding to the EST BG741742. The HBV and FR7 ORF were found in the same orientation. This is an example of a new gene, expressed in fetal and tumor tissues, identi®ed through the HBV-DNA integration analysis. The low amount of tumorous tissue allowed us to perform only one Northern blot analysis using poly(A) + RNA. This test showed abnormal bands in the tumorous FR7 tissue as compared to the FR7 sizes identi®ed in tumor cell lines ( Figure 3A) . The hybridization of the membrane with the HBV probe gave a very weak signal in the tumorous tissue consistent with one of the two bands found with the FR7 probe (data not shown). In order to con®rm the detection of a chimeric transcript, we synthetized a cDNA from poly(A) + RNA using the Marathon kit protocol, which includes ligation to the cDNA of linkers carrying the AP1 sequence. By using this approach we con®rmed the evidence for a chimeric transcript. In fact we ampli®ed the tumor derived cDNA with a primer on the HBV X sequence (MX2) and a primer on the cellular FR7 sequence (KP2). In repeated experiments we obtained a band of 720 bp (Figure 3, B1, lane 1) . This band was consistent with a 1300 bp band obtained on the FR7 cDNA by using a primer on the X ATG (X ATG) and a primer on the cDNA adaptor sequence (AP1) (Figure 3, B3) and corresponding to the size of the shorter transcript (1.3 Kb) detected by Northern blot in the tumor ( Figure 3A ). Since the primers MX2 and KP2 ampli®ed a 720 bp band also from the tumor DNA (Figure 3 , B1, lane 2), we ®nally tested the Marathon cDNA for the presence of genomic DNA with SERCA + RNA from tumorous (T) tissue FR7, HepG2, Hep3b and Huh7 HCCderived cell lines. Two bands of 1.3 and 5.6 Kb are clearly visible in the tumor, while transcripts of 3.7 and 8.5 Kb are expressed in HCC-derived cell lines. Northern blot analysis was performed as previously described (Chami et al., 2000) . FR7 probe was synthetized by amplifying normal liver RNA with primers KP1 (5'-CGTGGTAGTTTAAGTGTACA-3') and KP2 (5'-GATCAC-CAGGTGCTTAGTTTC-3') drawn on the FR7 unique sequence. (B1, B2 and B3) Ampli®cation of X/FR7 chimeric transcript. (B1) Ampli®cation with MX2 primer (on the HB X sequence: 5'-TGCCCAAGGTCTTACATAAGAGGA-3') and KP2 primer (on the unique FR7 sequence) of cDNA made from FR7 tumor poly (A) + RNA by using the Marathon kit (Clontech, Palo Alto, CA, USA) protocol according to manufacturer's instructions (lane 1), FR7 tumor DNA (lane 2), and normal liver DNA (lane 3). (7) indicates negative controls. MW: molecular weight marker. The picture shows the ampli®ed chimeric X/FR7 transcript (lane 1). The ampli®ed sequence does not contain intronic sequences, since a band of the same size is also obtained in the tumor DNA. In contrast, no chimeric sequence is detectable by amplifying normal liver DNA. (B2). The same samples as in B1 are ampli®ed with primers on exon 10 and exon 12 of the SERCA1 gene as described (Chami et al., 2001) . The expected size of the ampli®ed genomic sequences is 713 bp. The picture shows that there is no residual DNA in the cDNA obtained from FR7 tumorous tissue (lane 1). (B3) Ampli®cation of the FR7 tumor cDNA with the KP1 and KP2 primers (lane 1), and with a primer on the X ATG (5'-TTTCCATGGCTGCTAGGCTGACTGC-3') and a primer on the AP1 sequence (5'-CCATCCTAATACGACTCACTA-TAGGGC-3', present in the adaptor linkers blunt ligated to Marathon cDNA) followed by transfer and Southern blot hybridization with the FR7 probe. The picture shows that the probe is speci®c for the FR7 unique sequence (expected size: 190 bp, lane 1) and that the chimeric transcript ampli®ed has the size of 1300 bp (lane 2). With the Marathon protocol only the higher band (1300 bp) has to be taken into account, the lower bands being due to incomplete ampli®cations. (C) Western Blot analysis (Musahl et al., 1998) of tumorous (T) and non tumorous (NT) tissue from patient 77 (see Table 1 ) and normal liver (NL) by using the anti-hMCM8 antibody (D Gozuacik et al., submitted) . In addition to the expected hMCM8 size (95 kDa), a shorter band is clearly visible in the tumor (33 kDa). (D) Western blot analysis (Liu et al., 2001 ) of tumorous (T) and non tumorous tissue (NT) from patient 83 (see Table 1 ), normal liver (NL) and HeLa cells (positive control for hTERT expression) using anti-hTERT goat polyclonal antibody (Santa Cruz Biotechnology). The hTERT expression (136 kDa) is increased in the tumor tissue as compared to the non-tumorous tissue (see û actin normalization using anti-actin goat polyclonal antibody (Santa Cruz Biotechnology)). In addition, a higher band (170 kDa) is present in the tumor lane, indicating the hyperexpression of an unusual hTERT protein speci®c primers on exon 10 and 12. By using these primers we obtained the expected genomic 713 bp band in the tumor DNA and normal liver DNA (Figure 3,  B2, lanes 2 and 3) , but not in the tumor cDNA, therefore ruling out contamination of the tumor derived cDNA by cellular DNA. Taken overall, our results are therefore consistent with a chimeric HBV-FR7 transcript expressed in the FR7 tumor. Figure 4 Alignment of the last 100 nucleotides of the HBV sequences found at the integration site in the isolated 21 HBV/cellular DNA junctions. Nucleotides position is calculated according to the HBV adw sequence (accession number V00866). The same short sequence AGCA (in bold) is found at the junction in tumors 54 T, GR2s, and 95T Figure 5 Alignment of the 100 nucleotides of the cellular sequence preceding the integration site, and recovered from the data banks for 14 junctions. Highly homologous sequences (in bold) are present at the integration site in four tumors (ATGA in 100T/ ATGTA in 54T and GR2s/ATGAG in 63T). Short recurrent sequences are preceding (5 to 87 bp) the integration site: AAAGT (in pink) in eight tumors: 83T, 95T, FR2, GR1, GR2, GR2s, SA2 (twice), and SA5; AAATT (in orange) in three tumors: 95T, GR2, and SA1; AAAGA (in blue) in ®ve tumors: 63T, 83T, FR3, SA2 (twice) and SA2s; TAAGT (in dark green) in three tumors: 83T, FR2, and GR1; and AGAGT (in light green) in two tumors: 54T and 95T 
